Evotec Investor Presentation Deck

evotec B EVOroyalty PAGE 28 "Evotec Inside" Steady stream of high-value catalysts Selected pipeline events within next 12 - 24 months Phase III & registration (CHN) JingXin in insomnia (EVT201) • Phase II data with Bayer in DNP (BAY2395840) • Phase II initiation with Bayer in Gynaecology (BAY2395840) • Phase I data in Chikungunya virus (EVT894) ● Phase I data with BMS in CNS (EVT8683) • Phase I data with Kazia in Oncology (EVT801) • Phase lb/II initiation of Exscientia in Oncology (EXS21546) • Phase I initiation in Covid-19 / HBV (EVT075) • Phase I Initiation with Bayer in Kidney diseases • Phase I Initiation with Kidney diseases with other partners • Phase I initiation with BMS in CNS • Phase I Initiation with BMS in Oncology Multiple co-owned equity companies (not outlined here) will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, ...) DNP: Diabetic neuropathic pain CNS: Central nervous system Clinical Pre-clinical Discovery Molecule EVT201 Not Disclosed BAY2395840 CT7001 XP-105 EVT401 BAY2328065 EXS21546 CNTX 6016 EVT894 Not Disclosed Not Disclosed EVT801 EVT8683 TPM203 CT7001 CT7001 APN411 GLPGXXXX BAYXXXX QRB001 EVT075 Not disclosed EVTXXXX Therapeutic Area/Indication Insomnia (GABA-A) Infectious Disease (Antibody) Diabetic Neuropathic Pain (B1) Oncology (CDK7) Oncology (mTORC1/2) Immunology & Inflammation (P2X7) Gynaecology Oncology (various programmes) Pain (CB2) Chikungunya (Antibody) Neuroscience & Pain Neuroscience & Pain Oncology (VEGFR3) Neurodegeneration (elF2b activator) Pemphigus Vulgaris (ND) Oncology (CDK7) Oncology (CDK7) Oncology - Immunotherapy Fibrosis (not disclosed) Nephrology (not disclosed) Metabolic Diabetes (not disclosed) Covid-19/ HBV Various programmes CNS, Metabolic, Pain, ... Partner 京新药业 NGAN PHARMACEUTICAL DE SK bioscience Carrick. therapeutics XYNOMIC Pharma • 康恩贝集团 CONRA GROUP Exscientia DRIVEN BY KNOWLEDGE CENTREXION THERAPBUTIES NIH) SANOFI n.a. n.a. KAZIA Bristol Myers Squibb™ Topas Therapeutics Carrick Carrick SANOFI Galápagos QRbeta THERAPEUTICS n.a. APEIRON BIOLOGICS Bristol Myers Squibb >10 further programmes Discovery Pre-clinical Phase I Phase II Phase III Multiple programmes across nephrology, oncology, immunology among other therapeutic areas

View entire presentation